This is the authors' abstract. We don't add key points for this paper.
Introduction: Prophylaxis in mild and moderate hemophilia A has proven to be a fundamental pillar in managing the disease, significantly reducing bleeding episodes and improving patients' quality of life.Objective: To evaluate the efficacy of prophylaxis in 23 patients with mild-moderate hemophilia A and 10 patients with mild-moderate hemophilia B, comparing the results before and after switching to extended half-life concentrates.Method: Retrospective and observational study conducted by the HemoNorte group.Results: Previous studies have shown that even sporadic joint hemorrhages can lead to arthropathy and quality of life deterioration.This study underscores the importance of prophylaxis in preventing these long-term complications and the need for close monitoring to adjust treatment according to the patient's individual needs.Conclusions: The implementation of prophylaxis with extended half-life products offers multiple clinical and quality of life benefits for patients with mild to moderate hemophilia, justifying its continued and adapted use for each case.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Iglesias-Varela et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: